GATA-3-specific DNAzyme — A novel approach for stratified asthma therapy

European Journal of Immunology

Volumn 47, Issue 1, 2017, Pages 22-30

  Garn, Holger ^a   Renz, Harald ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

allergy; asthma; DNAzyme; GATA 3; Th2; type 2 immune responses

Indexed keywords

DEOXYRIBOZYME; TRANSCRIPTION FACTOR GATA 3;

ARTICLE; ASTHMA; ENZYME ACTIVITY; HUMAN; IMMUNE RESPONSE; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RNA CLEAVAGE; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; IMMUNITY; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE SUBPOPULATION; TH2 CELL;

ANIMALS; ASTHMA; DNA, CATALYTIC; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY; PHENOTYPE; T-LYMPHOCYTE SUBSETS; TH2 CELLS;

EID: 85009227409     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201646450     Document Type: Article

References (63)

1. Reddel, H. K., Bateman, E. D., Becker, A., Boulet, L.-P., Cruz, A. A., Drazen, J. M., Haahtela, T. et al., A summary of the new GINA strategy: a roadmap to asthma control. Eur. Respir. J. 2015. 46: 622–639.
2. Ober, C. and Yao, T.-C., The genetics of asthma and allergic disease: a 21st century perspective. Immunol. Rev. 2011. 242: 10–30.
3. Rava, M., Smit, L. A. M. and Nadif, R., Gene-environment interactions in the study of asthma in the postgenomewide association studies era. Curr. Opin. Allergy Clin. Immunol. 2015. 15: 70–78.
4. Licari, A., Marseglia, G., Castagnoli, R., Marseglia, A. and Ciprandi, G., The discovery and development of omalizumab for the treatment of asthma. Expert. Opin. Drug Discov. 2015. 10: 1033–1042.
5. Menzella, F., Lusuardi, M., Montanari, G., Galeone, C., Facciolongo, N. and Zucchi, L., Clinical usefulness of mepolizumab in severe eosinophilic asthma. Ther. Clin. Risk Manag. 2016. 12: 907–916.
6. Lloyd, C. M. and Hessel, E. M., Functions of T cells in asthma: more than just T(H)2 cells. Nat. Rev. Immunol. 2010. 10: 838–848.
7. Wenzel, S. E., Asthma phenotypes: the evolution from clinical to molecular approaches. Nat. Med. 2012. 18: 716–725.
8. Ray, A., Raundhal, M., Oriss, T. B., Ray, P. and Wenzel, S. E., Current concepts of severe asthma. J. Clin. Invest. 2016. 126: 2394–2403.
9. Holgate, S. T., Innate and adaptive immune responses in asthma. Nat. Med. 2012. 18: 673–683.
10. Bosnjak, B., Stelzmueller, B., Erb, K. J. and Epstein, M. M., Treatment of allergic asthma: modulation of Th2 cells and their responses. Respir. Res. 2011. 12: 114.
11. Fajt, M. L. and Wenzel, S. E., Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J. Allergy Clin. Immunol. 2015. 135: 299–310; quiz 311.
12. Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N. and Yancopoulos, G. D., Targeting key proximal drivers of type 2 inflammation in disease. Nat. Rev. Drug Discov. 2016. 15: 35–50.
13. Mitchell, P. D. and O'Byrne, P. M., Biologics and the lung: TSLP and other epithelial cell-derived cytokines in asthma. Pharmacol. Ther. 2016 in press. DOI: 10.1016/j.pharmthera.2016.06.009.
14. Brusselle, G. G., Provoost, S. and Maes, T., Prostaglandin D2 receptor antagonism: a novel therapeutic option for eosinophilic asthma? Lancet Respir. Med. 2016. 4: 676–677.
15. Zhang, D. H., Cohn, L., Ray, P., Bottomly, K. and Ray, A., Transcription factor GATA-3 is differentially expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene. J. Biol. Chem. 1997. 272: 21597–21603.
16. Maneechotesuwan, K., Xin, Y., Ito, K., Jazrawi, E., Lee, K.-Y., Usmani, O. S., Barnes, P. J. and Adcock, I. M., Regulation of Th2 cytokine genes by p38 MAPK-mediated phosphorylation of GATA-3. J. Immunol. 2007. 178: 2491–2498.
17. Patient, R. K. and McGhee, J. D., The GATA family (vertebrates and invertebrates). Curr. Opin. Genet. Dev. 2002. 12: 416–422.
18. Gao, J., Chen, Y.-H. and Peterson, L. C., GATA family transcriptional factors: emerging suspects in hematologic disorders. Exp. Hematol. Oncol. 2015. 4: 28.
19. Tindemans, I., Serafini, N., Di Santo, J. P. and Hendriks, R. W., GATA-3 function in innate and adaptive immunity. Immunity 2014. 41: 191–206.
20. Ho, I.-C., Tai, T.-S. and Pai, S.-Y., GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation. Nat. Rev. Immunol. 2009. 9: 125–135.
21. Yagi, R., Zhong, C., Northrup, D. L., Yu, F., Bouladoux, N., Spencer, S., Hu, G. et al., The transcription factor GATA3 is critical for the development of all IL-7Ralpha-expressing innate lymphoid cells. Immunity 2014. 40: 378–388.
22. Zhu, J., T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. Cytokine 2015. 75: 14–24.
23. Paul, W. E. and Zhu, J., How are T(H)2-type immune responses initiated and amplified? Nat. Rev. Immunol. 2010. 10: 225–235.
24. Chen, C. H., Zhang, D. H., LaPorte, J. M. and Ray, A., Cyclic AMP activates p38 mitogen-activated protein kinase in Th2 cells: phosphorylation of GATA-3 and stimulation of Th2 cytokine gene expression. J. Immunol. 2000. 165: 5597–5605.
25. Zhou, L., Striking similarity: GATA-3 regulates ILC2 and Th2 cells. Immunity 2012. 37: 589–591.
26. Klein Wolterink, R. G., Serafini, N., van Nimwegen, M., Vosshenrich, C. A. J., de Bruijn, M. J., Fonseca Pereira, D., Veiga Fernandes, H. et al., Essential, dose-dependent role for the transcription factor Gata3 in the development of IL-5+ and IL-13+ type 2 innate lymphoid cells. Proc. Natl. Acad. Sci. USA 2013. 110: 10240–10245.
27. Hoyler, T., Klose, C. S. N., Souabni, A., Turqueti-Neves, A., Pfeifer, D., Rawlins, E. L., Voehringer, D. et al., The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. Immunity, 2012. 37: 634–648.
28. Mjosberg, J., Bernink, J., Golebski, K., Karrich, J. J., Peters, C. P., Blom, B., te Velde, A. A. et al., The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity 2012. 37: 649–659.
29. Zhu, J., Yamane, H., Cote-Sierra, J., Guo, L. and Paul, W. E., GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res. 2006.16: 3–10.
30. Yagi, R., Zhu, J. and Paul, W. E., An updated view on transcription factor GATA3-mediated regulation of Th1 and Th2 cell differentiation. Int. Immunol. 2011. 23: 415–420.
31. Yagi, R., Junttila, I. S., Wei, G., Urban, J. F., JR, Zhao, K., Paul, W. E. and Zhu, J., The transcription factor GATA3 actively represses RUNX3 protein-regulated production of interferon-gamma. Immunity 2010. 32: 507–517.
32. Mantel, P.-Y., Kuipers, H., Boyman, O., Rhyner, C., Ouaked, N., Ruckert, B., Karagiannidis, C. et al., GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells. PLoS Biol. 2007. 5: e329.
33. Wohlfert, E. A., Grainger, J. R., Bouladoux, N., Konkel, J. E., Oldenhove, G., Ribeiro, C. H., Hall, J. A. et al., GATA3 controls Foxp3(+) regulatory T cell fate during inflammation in mice. J. Clin. Invest. 2011. 121: 4503–4515.
34. Wang, Y., Su, M. A. and Wan, Y. Y., An essential role of the transcription factor GATA-3 for the function of regulatory T cells. Immunity 2011. 35: 337–348.
35. Zhu, J., Min, B., Hu-Li, J., Watson, C. J., Grinberg, A., Wang, Q., Killeen, N. et al., Conditional deletion of Gata3 shows its essential function in T(H)1-T(H)2 responses. Nat. Immunol. 2004. 5: 1157–1165.
36. O'Garra, A. and Gabrysova, L., Transcription factors directing Th2 differentiation: gata-3 plays a dominant role. J. Immunol. 2016. 196: 4423–4425.
37. Taghon, T., Yui, M. A. and Rothenberg, E. V., Mast cell lineage diversion of T lineage precursors by the essential T cell transcription factor GATA-3. Nat. Immunol. 2007. 8: 845–855.
38. Zon, L. I., Gurish, M. F., Stevens, R. L., Mather, C., Reynolds, D. S., Austen, K. F. and Orkin, S. H., GATA-binding transcription factors in mast cells regulate the promoter of the mast cell carboxypeptidase A gene. J. Biol. Chem. 1991. 266: 22948–22953.
39. Nakamura, Y., Ghaffar, O., Olivenstein, R., Taha, R. A., Soussi-Gounni, A., Zhang, D. H., Ray, A. and Hamid, Q., Gene expression of the GATA-3 transcription factor is increased in atopic asthma. J. Allergy Clin. Immunol. 1999. 103: 215–222.
40. Hirasawa, R., Shimizu, R., Takahashi, S., Osawa, M., Takayanagi, S., Kato, Y., Onodera, M. et al., Essential and instructive roles of GATA factors in eosinophil development. J. Exp. Med. 2002. 195: 1379–1386.
41. Zon, L. I., Yamaguchi, Y., Yee, K., Albee, E. A., Kimura, A., Bennett, J. C., Orkin, S. H. and Ackerman, S. J., Expression of mRNA for the GATA-binding proteins in human eosinophils and basophils: potential role in gene transcription. Blood 1993. 81: 3234–3241.
42. Deng, Y.-Q., Yang, Y.-Q., Wang, S.-B., Li, F., Liu, M.-Z., Hua, Q.-Q. and Tao, Z.-Z., Intranasal administration of lentiviral miR-135a regulates mast cell and allergen-induced inflammation by targeting GATA-3. PLoS One 2015. 10: e0139322.
43. Erpenbeck, V. J., Hagenberg, A., Krentel, H., Discher, M., Braun, A., Hohlfeld, J. M. and Krug, N., Regulation of GATA-3, c-maf and T-bet mRNA expression in bronchoalveolar lavage cells and bronchial biopsies after segmental allergen challenge. Int. Arch. Allergy Immunol. 2006. 139: 306–316.
44. Taha, R., Hamid, Q., Cameron, L. and Olivenstein, R., T helper type 2 cytokine receptors and associated transcription factors GATA-3, c-MAF, and signal transducer and activator of transcription factor-6 in induced sputum of atopic asthmatic patients. Chest 2003. 123: 2074–2082.
45. Caramori, G., Lim, S., Ito, K., Tomita, K., Oates, T., Jazrawi, E., Chung, K. F. et al., Expression of GATA family of transcription factors in T-cells, monocytes and bronchial biopsies. Eur. Respir. J. 2001. 18: 466–473.
46. KleinJan, A., Klein Wolterink, R. G., Levani, Y., de Bruijn, M. J., Hoogsteden, H. C., van Nimwegen, M. and Hendriks, R. W., Enforced expression of Gata3 in T cells and group 2 innate lymphoid cells increases susceptibility to allergic airway inflammation in mice. J. Immunol. 2014. 192: 1385–1394.
47. Zhang, D. H., Yang, L., Cohn, L., Parkyn, L., Homer, R., Ray, P. and Ray, A., Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3. Immunity 1999. 11: 473–482.
48. Maneechotesuwan, K., Yao, X., Ito, K., Jazrawi, E., Usmani, O. S., Adcock, I. M. and Barnes, P. J., Suppression of GATA-3 nuclear import and phosphorylation: a novel mechanism of corticosteroid action in allergic disease. PLoS Med. 2009. 6: e1000076.
49. Liberman, A. C., Druker, J., Refojo, D., Holsboer, F. and Arzt, E., Glucocorticoids inhibit GATA-3 phosphorylation and activity in T cells. FASEB J. 2009. 23: 1558–1571.
50. Bergqvist, A., Andersson, C. K., Mori, M., Walls, A. F., Bjermer, L. and Erjefalt, J. S., Alveolar T-helper type-2 immunity in atopic asthma is associated with poor clinical control. Clin. Sci. 2015. 128: 47–56.
51. Nakamura, Y. and Hoshino, M., TH2 cytokines and associated transcription factors as therapeutic targets in asthma. Curr. Drug Targets Inflamm. Allergy 2005. 4: 267–270.
52. Potaczek, D. P., Garn, H., Unger, S. D. and Renz, H., Antisense molecules: a new class of drugs. J. Allergy Clin. Immunol. 2016. 137: 1334–1346.
53. Moschos, S. A., Usher, L. and Lindsay, M. A., Clinical potential of oligonucleotide-based therapeutics in the respiratory system. Pharmacol. Ther. 2016 in press. DOI: 10.1016/j.pharmthera.2016.10.009.
54. Finotto, S., de Sanctis, G. T., Lehr, H. A., Herz, U., Buerke, M., Schipp, M., Bartsch, B. et al., Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J. Exp. Med. 2001. 193: 1247–1260.
55. Lee, C.-C., Huang, H.-Y. and Chiang, B.-L., Lentiviral-mediated GATA-3 RNAi decreases allergic airway inflammation and hyperresponsiveness. Mol. Ther. 2008. 16: 60–65.
56. Sel, S., Wegmann, M., Dicke, T., Sel, S., Henke, W., Yildirim, A. O., Renz, H. and Garn, H., Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme. J. Allergy Clin. Immunol. 2008. 121: 910.
57. Dicke, T., Pali-Scholl, I., Kaufmann, A., Bauer, S., Renz, H. and Garn, H., Absence of unspecific innate immune cell activation by GATA-3-specific DNAzymes. Nucleic Acid Ther. 2012. 22: 117–126.
58. Fuhst, R., Runge, F., Buschmann, J., Ernst, H., Praechter, C., Hansen, T., von Erichsen, J. et al., Toxicity profile of the GATA-3-specific DNAzyme hgd40 after inhalation exposure. Pulm. Pharmacol. Ther. 2013. 26: 281–289.
59. Turowska, A., Librizzi, D., Baumgartl, N., Kuhlmann, J., Dicke, T., Merkel, O., Homburg, U. et al., Biodistribution of the GATA-3-specific DNAzyme hgd40 after inhalative exposure in mice, rats and dogs. Toxicol. Appl. Pharmacol. 2013. 272: 365–372.
60. Homburg, U., Renz, H., Timmer, W., Hohlfeld, J. M., Seitz, F., Luer, K., Mayer, A. et al., Safety and tolerability of a novel inhaled GATA3 mRNA targeting DNAzyme in patients with TH2-driven asthma. J. Allergy Clin. Immunol. 2015. 136: 797–800.
61. Krug, N., Hohlfeld, J. M., Kirsten, A.-M., Kornmann, O., Beeh, K. M., Kappeler, D., Korn, S. et al., Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N. Engl. J. Med. 2015. 372: 1987–1995.
62. Purath, U., Ibrahim, R., Zeitvogel, J., Renz, H., Runkel, F., Schmidts, T., Dobler, D. et al., Efficacy of T-cell transcription factor-specific DNAzymes in murine skin inflammation models. J. Allergy Clin. Immunol. 2016. 137: 644–647.e8.
63. Popp, V., Gerlach, K., Mott, S., Turowska, A., Garn, H., Atreya, R., Lehr, H.-A. et al., Rectal delivery of a DNAzyme that specifically blocks the transcription factor GATA3 reduces colitis in mice. Gastroenterology 2016 in press. DOI: 10.1053/j.gastro.2016.09.005.